|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses, deposits, and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Fixed assets, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Equity method investment - at fair value | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Operating lease liabilities, current portion | ||||||||||||||||||||
| Senior Secured Convertible Notes - at fair value | ||||||||||||||||||||
| Derivative liability - at fair value | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Rights liability | ||||||||||||||||||||
| Operating lease liabilities, less current portion | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series C Convertible Preferred Stock, stated value $1,058 at September 30, 2025, and issued and outstanding of 3,081 shares at September 30, 2025 and no shares issued and outstanding as of December 31, 2024 | ||||||||||||||||||||
| Stockholders’ Equity (Deficit): | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series B Convertible Preferred Stock | ||||||||||||||||||||
| Series C Convertible Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Total preferred stock | ||||||||||||||||||||
| Common stock, $0.001 par value. Authorized, 25,000,000 shares (Note 12); 6,269,418 and 927,934 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total PAVmed Stockholders’ Equity (Deficit) | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total Stockholders’ Equity (Deficit) | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
